Genmab — April 2020
-
https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(20)30143-9/fulltext
Evolving role of Daratumumab: From backbencher to a frontline agent https://sci-hub.tw/https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(20)30143-9/fulltext -
US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time https://www.finanzen.ch/nachrichten/aktien/us-fda-and-ema-accept-applications-for-roches-ocrevus-ocrelizumab-shorter-2-hour-infusion-time-1029105760
-
Novartis starting a new "An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab (ARTIOS)" https://www.clinicaltrials.gov/ct2/show/NCT04353492?cond=Multiple+Sclerosis&sfpd_s=04%2F06%2F2020&sfpd_d=14&sel_rss=new14
-
topf empfehlung! No idea who the guy is, but as it is quiet here, just for fun, from minute 4. He can't really get the market cap right, but he thinks they can do something for Corona
'Ein heizer übernahmekandidat"
https://www.youtube.com/watch?v=7meqXbfvH6Q -
NBI still very strong...
-
-
Results of the safety run-in phase of the ANDROMEDA trial in patients with newly diagnosed AL amyloidosis https://multiplemyelomahub.com/medical-information/results-of-the-safety-run-in-phase-of-the-andromeda-trial-in-patients-with-newly-diagnosed-al-amyloidosis
-
Er der ingen kurser der opdateres iøjeblikket
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind